Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia

Most cancer cells have high need for nicotinamide adenine dinucleotide (NAD(+)) to sustain their survival. This led to the development of inhibitors of nicotinamide (NAM) phosphoribosyltransferase (NAMPT), the rate-limiting NAD(+) biosynthesis enzyme from NAM. Such inhibitors kill cancer cells in pr...

Descripción completa

Detalles Bibliográficos
Autores principales: ElMokh, Oussama, Matsumoto, Saki, Biniecka, Paulina, Bellotti, Axel, Schaeuble, Karin, Piacente, Francesco, Gallart-Ayala, Hector, Ivanisevic, Julijana, Stamenkovic, Ivan, Nencioni, Alessio, Nahimana, Aimable, Duchosal, Michel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993809/
https://www.ncbi.nlm.nih.gov/pubmed/35396381
http://dx.doi.org/10.1038/s41419-022-04763-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993809/
https://www.ncbi.nlm.nih.gov/pubmed/35396381
http://dx.doi.org/10.1038/s41419-022-04763-3

Ejemplares similares